SnapShot: Cancer Immunotherapy with Oncolytic Viruses

Shashi Gujar; John Bell; Jean Simon Diallo

doi:10.1016/j.cell.2019.01.051

SnapShot: Cancer Immunotherapy with Oncolytic Viruses

Shashi Gujar, John Bell, Jean Simon Diallo

Medicine

Producción científica: Contribución a una revista › Encuesta corta › revisión exhaustiva

70 Citas (Scopus)

Resumen

Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.

Idioma original	English
Páginas (desde-hasta)	1240-1240.e1
Publicación	Cell
Volumen	176
N.º	5
DOI	https://doi.org/10.1016/j.cell.2019.01.051
Estado	Published - feb. 21 2019

Nota bibliográfica

Publisher Copyright:
© 2019

ASJC Scopus Subject Areas

General Biochemistry,Genetics and Molecular Biology

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/j.cell.2019.01.051

Otros archivos y enlaces

Citar esto

@article{8bcc338fe06c44169d7de1d0b9d20b3d,

title = "SnapShot: Cancer Immunotherapy with Oncolytic Viruses",

abstract = "Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.",

author = "Shashi Gujar and John Bell and Diallo, {Jean Simon}",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = feb,

day = "21",

doi = "10.1016/j.cell.2019.01.051",

language = "English",

volume = "176",

pages = "1240--1240.e1",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - SnapShot

T2 - Cancer Immunotherapy with Oncolytic Viruses

AU - Gujar, Shashi

AU - Bell, John

AU - Diallo, Jean Simon

PY - 2019/2/21

Y1 - 2019/2/21

N2 - Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.

AB - Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.

UR - http://www.scopus.com/inward/record.url?scp=85061673481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061673481&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2019.01.051

DO - 10.1016/j.cell.2019.01.051

M3 - Short survey

C2 - 30794777

AN - SCOPUS:85061673481

SN - 0092-8674

VL - 176

SP - 1240-1240.e1

JO - Cell

JF - Cell

IS - 5

ER -

SnapShot: Cancer Immunotherapy with Oncolytic Viruses

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto